<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05076591</url>
  </required_header>
  <id_info>
    <org_study_id>IMM2902-101</org_study_id>
    <nct_id>NCT05076591</nct_id>
  </id_info>
  <brief_title>IMM2902, a HER2/SIRPα Bispecific mAb-Trap Antibody-receptor Fusion Protein, in Patients With HER2-expressing Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1, Open-Label, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of IMM2902 in Patients With HER2-Expressing Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a first-in-human, open label, multi-center, dose escalation phase 1a study&#xD;
      followed by a disease-specific dose expansion phase 1b study to evaluate the safety,&#xD;
      efficacy, and pharmacokinetics (PK) of IMM2902, a HER2/SIRPα bispecific mAb-Trap&#xD;
      antibody-receptor fusion protein, in patients with HER2-expressing advanced solid tumor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-Limiting Toxicity (DLT)</measure>
    <time_frame>48 Weeks</time_frame>
    <description>All toxicities will be graded according to the NCI CTCAE Version 5.0, which provides additional guidance for AEs not specifically mentioned in CTCAE. A DLTs is defined as any Grade 3 or greater AE that is assessed as related to study treatment that occurs during the 4-week DLTs observation period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>maximum tolerated dose (MTD) of IMM2902</measure>
    <time_frame>48 Weeks</time_frame>
    <description>Toxicity will be evaluated according to the NCI CTCAE Version 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>dose for expansion (RDE) of IMM2902</measure>
    <time_frame>48 Weeks</time_frame>
    <description>Toxicity will be evaluated according to the NCI CTCAE Version 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with Adverse Events（AEs）</measure>
    <time_frame>48 Weeks</time_frame>
    <description>Graded according to the NCI CTCAE V5.0</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <condition>Advanced Breast Cancer</condition>
  <condition>Advanced Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>IMM2902</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMM2902 Dose escalation: 0.03, 0.1, 0.25, 0.5, 1.0, 1.5, and 2.0 mg/kg through intravenous administration weekly up to 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMM2902</intervention_name>
    <description>a recombinant bispecific monoclonal antibody with high affinity to the dual targets, HER2 and CD47</description>
    <arm_group_label>IMM2902</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Histologically or cytologically confirmed HER2-expressing advanced solid malignancy,&#xD;
             who have been treated with at least one regimen of prior systemic therapy, or who&#xD;
             refuse systemic therapy, and for which there is no curative therapy available.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.&#xD;
&#xD;
          -  Completion of prior chemotherapy systemic anticancer therapy at least 2 weeks prior to&#xD;
             study entry.&#xD;
&#xD;
          -  Radiation therapy must be completed at least 2 weeks prior to study entry. Radiated&#xD;
             lesions may not serve as measurable disease unless they have been radiated ≥12 months&#xD;
             prior to enrollment.&#xD;
&#xD;
          -  Patients must have adequate organ and bone marrow function within 14 days of first&#xD;
             dose of study drug administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior anti-cancer therapy including chemotherapy, hormonal therapy, or investigational&#xD;
             agents within 2 weeks or within at least 4 half-lives prior to IMM2902 dosing (up to a&#xD;
             maximum of 4 weeks).&#xD;
&#xD;
          -  Anthracyclines within 3 months before first IMM2902 dosing or lifetime load exceeding&#xD;
             300 mg/m² adriamycin or equivalent.&#xD;
&#xD;
          -  Prior treatment with CD47 or SIRPα-targeting agents.&#xD;
&#xD;
          -  Trastuzumab, pertuzumab, lapatinib, tucatinib or T-DM1 within 3 weeks before first&#xD;
             IMM2902 dosing.&#xD;
&#xD;
          -  Known active infection including tuberculosis, hepatitis B, hepatitis C, or human&#xD;
             immunodeficiency virus.&#xD;
&#xD;
          -  Known inherited or acquired bleeding disorders.&#xD;
&#xD;
          -  History of hemolytic anemia or Evans syndrome, sickle cell disease, thalassemia, G6PD&#xD;
             deficiency, hereditary spherocytosis, or hypersplenism in the last 3 months.&#xD;
&#xD;
          -  Current or prior use of immunosuppressive therapy within 14 days before the first dose&#xD;
             of IMM2902.&#xD;
&#xD;
          -  Receipt of live attenuated vaccination within 30 days prior to registration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheng Huang, MD</last_name>
    <role>Study Director</role>
    <affiliation>VP，Clinical Development</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qianwen Shao</last_name>
    <phone>+8617709180861</phone>
    <email>qianwen.shao@immuneonco.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>October 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

